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AbstrAct
background: In invasive breast cancer, her2 is a well-established negative prognostic factor. however, its significance on 
the prognosis of ductal carcinoma in situ (DcIs) of the breast is unclear. as a result, the impact of her2-directed therapy on  
her2-positive DcIs is unknown and is currently the subject of ongoing clinical trials. 
In this study, we aim to determine the possible impact of her2-directed targeted therapy on survival outcomes for  
her2-positive DcIs patients.
Materials and methods: The National cancer Data Base (NcDB) was used to retrieve patients with biopsy-proven DcIs diag-
nosed from 2004–2015. patients were divided into two groups based on the adjuvant therapy they received: systemic her2-
directed targeted therapy or no systemic therapy. statistics included multivariable logistic regression to determine factors 
predictive of receiving systemic therapy, Kaplan-Meier analysis to evaluate overall survival (Os), and cox proportional hazards 
modeling to determine variables associated with Os.
results: altogether, 1927 patients met inclusion criteria; 430 (22.3%) received her2-directed targeted therapy; 1497 (77.7%) 
did not. patients who received her2-directed targeted therapy had a higher 5-year Os compared to patients that did not 
(97.7% vs. 95.8%, p = 0.043). This survival benefit remained on multivariable analysis. Factors associated with worse Os on 
multivariable analysis included charlson-Deyo comorbidity score ≥ 2 and no receipt of hormonal therapy.
conclusion: In this large study evaluating her2-positive DcIs patients, the receipt of her2-directed targeted therapy was 
associated with an improvement in Os. The results of currently ongoing clinical trials are needed to confirm this finding.
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Introduction
Ductal carcinoma in situ (DCIS) of the breast is 
a pre-invasive form of breast cancer that is defined 
by neoplastic proliferation of epithelial cells that is 
confined to the mammary ductal system [1]. It is 
estimated that DCIS makes up approximately 20% 
of all new diagnoses of breast cancer and up to 40% 
of all cases detected via mammogram [2–4]. While 
DCIS is a pre-cancerous lesion, finding DCIS war-
rants treatment as it is believed to be a precursor 
to invasive breast cancers (IBC) [5]. As a result, 
considerable research efforts have been aimed at 
understanding the mechanisms of this progression.
 Although DCIS has been thought to be single 
disease entity, there is evidence that DCIS, much 
like invasive breast cancer, encompasses a broad 
and heterogenous group of diseases that can be dif-
ferentiated by varying degrees of biological aggres-
siveness [6]. For example, classifying DCIS similarly 
to IBC may be a way to determine prognoses based 
on disease biology [7, 8]. However, individualizing 
treatment options and management based on this 
information is still controversial. While patients 
with IBC receive personalized systemic treatment 
based on their specific molecular subtype, patients 
with DCIS are treated fairly uniformly. Indeed, after 
initial local therapy (surgery with or without radio-
therapy), the hormone receptor status is the only 
factor that may affect systemic treatment [9–11]. 
 However, there is growing interest in using 
HER2-targeted therapy for HER2-amplified DCIS 
patients. While there is conflicting evidence on the 
effect of HER2 positivity on disease characteristics 
and patient outcomes [7, 8, 12–17], there remains 
strong interest in the role of HER2-targeted thera-
py. The National Surgical Adjuvant Breast and Bow-
el Project (NSABP) is currently running a clinical 
trial (B-43) examining the effect of trastuzumab 
on the risk of in-breast tumor recurrence for pa-
tients with HER2 positive DCIS [4]. Given the lack 
of evidence and defined management guidelines, 
we aimed to use the National Cancer Data Base 
(NCDB) to determine the effects of HER2-targeted 
therapy on survival outcomes. 
Materials and methods
This study used the NCDB, which is a hospi-
tal-based cancer registry sponsored by the Ameri-
can College of Surgeons (ACoS) and the Ameri-
can Cancer Society. It collects data from over 1500 
hospitals with ACoS-accredited cancer programs, 
accounting for 70% of all newly-diagnosed cases 
in the United States [18–22]. The most recent data 
from the NCDB included data from 2004–2015. 
A case list of patients with biopsy-proven DCIS 
was retrieved from the NCDB. Diagnosis was based 
on the International Classification of Disease for 
Oncology, third edition (ICD-O-3) codes of 8201, 
8230, 8500, 8501, 8503, 8507, and 8522. Patients 
with invasive breast cancer were specifically exclud-
ed. In order to be included in the study, patients 
were required to have a positive HER2 status. No 
specific cutoffs for HER2 positivity are mandated 
by the NCDB but each institution is accredited by 
the American College of Surgeons and pathology 
reports are required to follow the format, criteria, 
and guidelines of the College of American Patholo-
gists [23]. 
Patient characteristics retrieved and recorded in-
cluded age, race, Charlson-Deyo comorbidity score, 
type of insurance, income, facility type, margin sta-
tus, receipt of hormonal therapy, estrogen recep-
tor (ER) status, progesterone receptor (PR) status, 
and DCIS grade. Patients who received systemic 
therapy were coded as having received HER2-tar-
geted therapy. Because patients with DCIS are not 
candidates for non-endocrine, cytotoxic systemic 
therapy, this assumption was felt to be reasonable. 
Patients were divided into two cohorts: those who 
received HER2-targeted therapy and those who did 
not. 
All statistical tests were two-sided, with a thresh-
old of p < 0.05 for statistical significance, and were 
performed using STATA (version 14, StataCorp, 
College Station, TX). The c2 test analyzed categori-
cal proportions between groups. Univariable and 
multivariable logistic regression modeling was uti-
lized to determine characteristics that were predic-
tive of the receipt of HER2-targeted therapy. The 
Kaplan-Meier method was used for survival analy-
sis, and comparisons between the two treatment 
paradigms were performed with the log-rank test 
for all patients. Overall survival (OS) was defined 
as the interval between the date of diagnosis and 
the date of death or last contact. Multivariable Cox 
proportional hazards modeling was additionally 
used to identify variables associated with OS in the 
entire cohort.
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results
Altogether, 1927 patients met the inclusion 
criteria. The majority of patients in the cohort 
were over the age of 50, Caucasian, had a Charl-
son-Deyo Comorbidity Score of 0 and were treated 
at a non-academic facility. Overall, 430 (22.3%) re-
ceived HER2-directed targeted therapy, while 1497 
(77.7%) did not. Patient characteristics for the two 
groups are listed in Table 1. Patients with ER(–) 
disease were more likely to receive HER2-directed 
targeted therapy. There was no relation between 
table 1. Baseline characteristics of patients in each of the cohorts
Characteristic
HER2-targeted therapy
(n = 430) (%)
No HER2-targeted therapy
(n = 1497) (%)
p-value
Age (years) 0.601
≤ 50 92 (21.4%) 303 (20.2%)
> 50 338 (78.6%) 1194 (79.8%)
race 0.778
caucasian 371 (86.3%) 1271 (84.9%)
african american 41 (9.5%) 157 (10.5%)
Other/ not recorded 18 (4.2%) 69 (4.6%)
charlson-Deyo score 0.813
0 374 (87.0%) 1319 (88.1%)
1 50 (11.6%) 18 (10.6%)
≥ 2 6 (1.4%) 20 (1.3%)
Insurance 0.670
Medicaid 25 (5.8%) 86 (5.7%)
private 274 (63.7%) 902 (60.3%)
Medicare 116 (27.0%) 455 (30.4%)
Uninsured 8 (1.9%) 24 (1.6%)
Government/other 7 (1.6%) 30 (2.0%
Income 0.457
≤ 62999 UsD 281 (65.4%) 938 (62.7%)
≥ 63000 UsD 147 (34.2%) 555 (37.1%)
Not recorded 2 (0.5%) 4 (0.3%)
Facility type 0.432
academic 108 (25.1%) 417 (27.9%)
Non-academic 317 (73.7%) 1068 (71.3%)
Not recorded 5 (1.2%) 12 (0.8%)
Margin status 0.306
Negative 416 (96.7%) 1440 (96.2%)
positive 10 (2.3%) 50 (3.3%)
Not recorded 4 (0.9%) 7 (0.5%)
Hormonal therapy 0.898
Yes 220 (51.2%) 777 (51.9%)
No 167 (38.8%) 581 (38.8%)
Not recorded 43 (10.0%) 139 (9.3%)
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the receipt of HER2-directed targeted therapy and 
insurance type, income, facility type, margin status, 
grade, or receipt of hormonal therapy.
The Kaplan-Meier curves comparing survival for 
patients either receiving treatment with or without 
HER2- directed therapy are illustrated in Figure 1. 
Patients who received HER2–directed targeted 
therapy had a higher 5-year OS compared to pa-
tients that did not (97.7% vs. 95.8%, p = 0.043, 
Fig. 1). This survival benefit for HER2-directed tar-
geted therapy remained statistically significant on 
multivariable analysis. On multivariable analysis, 
factors associated with worse OS included Charl-
son-Deyo Comorbidity Score ≥ 2 and no receipt 
of hormonal therapy. The results of the univariable 
and multivariable analysis are displayed in Table 2.
table 1. Baseline characteristics of patients in each of the cohorts
Characteristic
HER2-targeted therapy
(n = 430) (%)
No HER2-targeted therapy
(n = 1497) (%)
p-value
Estrogen receptor status 0.034
positive 261 (60.7%) 992 (66.3%)
Negative 169 (39.3%) 499 (33.3%)
Not recorded 0 (0.0%) 6 (0.4%)
Progesterone receptor status 0.665
positive 199 (46.3%) 726 (48.5%)
Negative 221 (51.4%) 742 (49.6%)
Not recorded 10 (2.3%) 29 (1.9%)
Grade 0.295
1 13 (3.0%) 57 (3.8%)
2 65 (15.1%) 278 (18.6%)
3 275 (64.0%) 897 (59.9%)























Herceptin 430 110 0 0
None 1497 373 8 0
Figure 1. Overall survival stratified by receipt of her2-directed targeted therapy
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Discussion
To the best of our knowledge, this study repre-
sents the largest study of HER2 positive DCIS pa-
tients. In addition, this analysis is the first to exam-
ine the potential impact of HER2-directed targeted 
therapy on survival outcomes for DCIS patients. 
Several observations can be made from this analysis. 
First, as expected, the overall survival of all patients 
with HER2 positive DCIS was very high, with OS 
rates at five years > 95% with or without the use 
of HER2-targeted therapy. Second, the presumed 
use of HER2-targeted therapy was associated with 
improved OS amongst patients with HER2 positive 
DCIS. These results are interesting and highlight the 
importance of the NSABP B-43 clinical trial results, 
as the patient characteristics of our study popula-
tion are similar to patients that were enrolled in the 
B-43 trial. A comparison of the patient character-
istics collected from that trial with a comparison 
of our data is displayed in Table 3. The distribution 
of age and hormone receptor status between the 
two cohorts was similar. Our study population had 
slightly lower rates of high-grade DCIS compared to 
the B-43 cohort, which may have been due to high-
er rates of unrecorded tumor grade in the NCDB. 
Overall, HER2 positivity in our cohort was associ-
ated with high nuclear grade, which is concordant 
with the existing literature [4, 24–26]. 
This is the first study to suggest that the use of 
HER2-directed therapy is associated with an im-
provement in overall survival amongst patients with 
HER2 positive DCIS. Our study is also the first to 
indicate a potential clinical benefit on survival out-
comes for this patient population. Previous work 
has demonstrated that trastuzumab can effectively 
cross the basement membrane of the ductal system 
and may have clinical efficacy for HER2 positive 
DCIS [27–29]. If the NSABP trial has similar find-
ings, HER2-directed targeted therapy may allow 
more treatment options for patients with DCIS, 
especially those with HR receptor negative disease. 
In addition, due to the significant heterogeneity of 
DCIS, another available targeted treatment option 
opens the door for more personalized cancer treat-
ment. Finally, HER2-directed targeted therapy may 
serve as a mechanism to reduce the risk of progres-
sion of DCIS to invasive cancer, opening up the 
possibility of HER2-directed targeted therapy as 
a form of monotherapy.
Overall, HER2-directed therapy (in the form 
of trastuzumab) has demonstrated a strong safety 
record. In a preliminary report of HER2 positive 
DCIS patients in NSABP B-43, 5% of patients in the 
trastuzumab arm reported grade 3 toxicities with 
no cases of grade 4 or 5 toxicities [4]. In invasive 
breast cancer, trastuzumab has been studied exten-
sively and found to have an acceptable safety pat-
tern, even with regards to cardiotoxicity [30–32]. 
However, when compared to invasive cancer, the 
therapeutic ratio of trastuzumab for HER2 posi-
tive DCIS may not be as strong. DCIS patients as 
table 3. comparison of her2 positive DcIs patient characteristics between our study and the NsaBp B-43 trial [4]
Current Study NSABP B-43 trial [4] 
Characteristic
HER2-targeted therapy 
(n = 430) (%)
No HER2-targeted 
therapy 
(n = 1497) (%)
HER2-targeted therapy 
(n = 713) (%)
No HER2-targeted 
therapy 
(n = 715) (%)
Age (years)
≤ 50 92 (21.4%) 303 (20.2%) 161 (22.6%) 164 (22.9%)
> 50 338 (78.6%) 1194 (79.8%) 552 (77.4%) 551 (77.1%)
Estrogen receptor status
positive 261 (60.7%) 992 (66.3%) 423 (59.3%) 409 (57.2%)
Negative 169 (39.3%) 499 (33.3%) 290 (40.7%) 304 (42.5%)
Not recorded 0 (0.0%) 6 (0.4%) 0 (0.0%) 2 (0.3%)
Grade
Well differentiated 13 (3.0%) 57 (3.8%) 10 (1.4%) 5 (0.7%)
Moderately differentiated 65 (15.1%) 278 (18.6%) 108 (15.1%) 122 (17.1%)
poorly differentiated 275 (64.0%) 897 (59.9%) 595 (83.5%) 588 (82.2)
Not recorded 77 (17.9%) 265 (17.7%) – –
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a whole do very well in terms of survival outcomes. 
Indeed, our study found an OS of 95.8% at five 
years. Even with a survival benefit at 5 years for 
HER2-directed therapy, it is possible that with long 
term follow-up the toxicity of therapy may erase 
any benefits. As a result, it is likely that not all HER2 
positive DCIS patients will benefit from treatment, 
only patients at the highest risk. The results of the 
NSABP B-43 trial are likely to be very helpful in 
delineating which patients receive benefit.
The cost of therapy must also be taken into ac-
count. As a monoclonal antibody, the costs of man-
ufacturing trastuzumab are already significant, even 
without including costs associated with administra-
tion, monitoring, and staffing [33]. For a patient 
population that already does well, cost-effectiveness 
studies will need to be performed to determine the 
societal value of more aggressive treatment, espe-
cially in the current health care climate of continu-
ously rising (and often prohibitive) costs.
Our study has several limitations due to its reli-
ance on the NCDB. First, our study had a relatively 
short follow-up due to the lack of widespread HER2 
reporting in the NCDB until more recently. How-
ever, there was still a significant difference in sur-
vival based on receipt of HER2-directed therapy, 
although it is possible that the survival curves may 
plateau or cross with additional follow-up. Next, we 
must acknowledge the retrospective nature of the 
study with all its associated biases. HER2 status is 
not normally assessed and reported in DCIS; there 
may be potential bias in the patients who underwent 
HER2 testing. This may explain why the percentage 
of patients receiving systemic targeted therapy in 
our study (22.3%) was higher than expected; cur-
rently, there is no standard clinical indication for 
non-endocrine systemic therapy. In addition, the 
NCDB does not record the use of specific targeted 
agents. We had to assume that patients recorded as 
receiving systemic therapy received HER2-directed 
targeted therapy. Although this assumption cannot 
be assured, it is highly unlikely that DCIS patients 
received non-endocrine cytotoxic chemotherapy; 
it is much more likely that these patients received 
HER2-directed therapy, especially given that these 
patients all had HER2 positive disease.
The lack of central review of pathology speci-
mens is another limitation. However, our patient 
characteristics were similar to those found in the 
NSABP B-43 trial (which did have central pathol-
ogy review), giving credence to our findings. We 
must also point out that the definitions for HER2 
positivity have changed over time. In 2007, the defi-
nition of HER2 positivity was > 30% of tumor cells 
positive by immunohistochemistry (IHC) or a ratio 
of HER2 to CEP17 of > 2.2 by in-situ hybridization 
(ISH) [34]. In 2013, this definition was adjusted 
to > 10% of tumor cells positive by IHC, which was 
consistent with the entry criteria for trials examin-
ing the role of trastuzumab [34]. Alternatively, for 
ISH, a HER2/CEP17 ratio of > 2 (depending on 
the number of signals per cell) was used as a cut-
off for HER2 positivity [34]. Additional changes 
to the guidelines were made in 2018 [35]. Given, 
the generally lower thresholds for HER2 positivity 
in these refinements, the number of DCIS patients 
defined as HER2 positive would be expected to in-
crease. The impact this would have on the benefit of 
HER2-directed targeted therapy is unclear.
conclusions
In the treatment of HER2-positive DCIS pa-
tients, the presumed receipt of HER2-directed tar-
geted therapy was associated with an improvement 
in OS. This survival benefit remained statistically 
significant on multivariable analysis. This study is 
the largest study of HER2 positive DCIS patients to 
date, and our findings highlight the need for addi-
tional prospective data; we eagerly await the results 
of the currently ongoing clinical trials on this topic.
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